Design, Synthesis and Antidiabetic Activity of Novel Sulfamoyl Benzamide Derivatives as Glucokinase Activators

Home > 2018, Vol. 6 No. 2 > Design, Synthesis and Antidiabetic Activity of Novel Sulfamoyl Benzamide Derivatives as Glucokinase Activators
Published: November 2, 2018
Download PDF
Download XML | Download HTML

Authors

  • Ajmer Singh GrewalChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India
  • Kapil SharmaJan Nayak Ch. Devi Lal Memorial College of Pharmacy, Sirsa, 125055, Haryana, India
  • Sukhbir SinghChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India
  • Vikramjeet SinghDepartment of Pharmaceutical Sciences, GJUS&T, Hisar, 125001, Haryana, India
  • Deepti PanditaAmity Institute of Molecular Medicine & Stem Cell Research, Amity University, Noida, 201303, Uttar Pradesh, India
  • Viney LatherAmity Institute of Pharmacy, Amity University, Noida, 201303, Uttar Pradesh, India
DOI Number
https://doi.org/10.15415/jptrm.2018.62008
Keywords
Antidiabetic activity, Benzamides, Diabetes mellitus, Glucokinase, GK activators, Molecular Docking

Abstract

The present work has been planned to design, synthesize and evaluate the antidiabetic potential of a series of sulfamoyl benzamide derivatives as potential glucokinase (GK) activators. A new series of sulfamoyl benzamide derivatives was synthesized starting from 3-nitrobenzoic acid and characterized. In silico docking studies were performed to determine the binding interactions for the best fit conformations in the allosteric site of GK enzyme. Based on the results of in silico studies, the selected molecules were tested for their antidiabetic activity in animal studies (alloxan induced diabetic animal model). Compound 7 exhibited highest antidiabetic activity in animal studies. The results of in vivo antidiabetic activity studies were found to be in parallel to that of docking studies. These newly synthesized sulfamoyl benzamide derivatives thus can be treated as the initial hits for the development of novel, safe, effective and orally bioavailable GK activators as therapeutic agents for the treatment of type 2 diabetes.

References

  • Akinola, O., Gabriel, M., Suleiman, A., and Olorunsogbon, F. (2012). Treatment of alloxaninduced diabetic rats with metformin or glitazones is associated with amelioration of hyperglycaemia and neuroprotection. The Open Diabetes Journal, 5, 8–12. https://doi.org/10.2174/1876524601205010008
  • Bastaki, S. (2005). Diabetes mellitus and its treatment. International Journal of Diabetes Metabolism, 13, 111–134.
  • Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813–820. https://doi.org/10.1038/414813
  • Cade, W. T. (2008). Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical Therapy, 88, 1322–1335. https://doi.org/10.2522/ptj.20080008
  • Charaya N., Pandita D., Grewal A. S., and Lather V.(2018). Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Computational Biology and Chemistry, 73, 221–229. https://doi.org/10.1016/j.compbiolchem.2018.02.018
  • Cheruvallath, Z. S., Gwaltney, S. L., Sabat, M., Tang, M., Feng, J., Wang, H., et al. (2013). Design, synthesis and SAR of novel glucokinase activators. Bioorganic and Medicinal Chemistry Letters, 23(7), 2166–2171. https://doi.org/10.1016/j.bmcl.2013.01.093
  • Coghlan, M. and Leighton, B. (2008). Glucokinase activators in diabetes management. Expert Opinion on Investigational Drugs, 17(2), 145–167. https://doi.org/10.1517/13543784.17.2.145
  • Filipski, K. J., Guzman-Perez, A., Bian, J., Perreault, C., Aspnes, G. E., Didiuk, M. T., et al. (2013). Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorganic and Medicinal Chemistry Letters, 23(16), 4571–4578. https://doi.org/10.1016/j.bmcl.2013.06.036
  • Grewal, A. S., Sekhon, B. S., and Lather, V. (2014). Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Reviews in Medicinal Chemistry, 14(7), 585–602. https://doi.org/10.2174/1389557514666140722082713
  • Grewal, A. S., Bhardwaj, S., Pandita, D., Lather, V. and Sekhon, B. S. (2016). Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Reviews in Medicinal Chemistry, 16(2), 120–162. https://doi.org/10.2174/1389557515666150909143737
  • Grewal, A. S., Lather, V., Pandita, D. and Bhayana, G. (2017). Synthesis, docking and biological evaluation of phenylacetic acid and trifluoromethylphenyl substituted benzamide derivatives as potential PPARδ agonists. Letters in Drug Design and Discovery, 14(11), 1239–1251. https://doi.org/10.2174/1570180814666170327164443
  • Grewal, A. S., Viney Lather, V., Pandita, D. and Dalal, R. (2017). Synthesis, docking and anti-inflammatory activity of triazole amine derivatives as potential phosphodiesterase-4 inhibitors. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 16(1), 58–67. https://doi.org/10.2174/1871523016666170616115752
  • Hinklin, R. J., Boyd, S. A., Chicarelli, M. J., Condroski, K. R., DeWolf, W. E., Lee, P. A., et al. (2013). Identification of a new class of glucokinase activators through structure-based design. Journal of Medicinal Chemistry, 56(19), 7669–7678. https://doi.org/10.1021/jm401116k
  • Iino, T., Sasaki, Y., Bamba, M., Mitsuya, M., Ohno, A., Kamata, K., et al. (2009). Discovery and structureactivity relationships of a novel class of quinazoline glucokinase activators. Bioorganic and Medicinal Chemistry Letters, 19(19), 5531–5538. https://doi.org/10.1016/j.bmcl.2009.08.064
  • Iino, T., Hashimoto, N., Hasegawa, T., Chiba, M., Eiki, J. and Nishimura, T. (2010). Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: impacts of glutathione trapping on covalent binding. Bioorganic and Medicinal Chemistry Letters, 20(5), 1619–1622. https://doi.org/10.1016/j.bmcl.2010.01.041
  • Ishikawa, M., Nonoshita, K., Ogino, Y., Nagae, Y., Tsukahara, D., Hosaka, H., et al. (2009). Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorganic and Medicinal Chemistry Letters, 19(15), 4450–4454. https://doi.org/10.1016/j.bmcl.2009.05.038
  • Kohei, K. (2010). Pathophysiology of type 2 diabetes and its treatment policy. Japan Medical Association Journal, 53, 41–46.
  • Li, F., Zhu. Q., Zhang, Y., Feng, Y., Leng, Y. and Zhang, A. (2010). Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazole-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators. Bioorganic and Medicinal Chemistry, 18(11), 3875–3884. https://doi.org/10.1016/j.bmc.2010.04.038
  • Li, Y. Q., Zhang, Y. L., Hu, S. Q., Wang, Y. L., Song, H. R., Feng, Z.Q. et al. (2011). Design, synthesis and biological evaluation of novel glucokinase activators. Chinese Chemical Letters, 22(1), 73–76. https://doi.org/10.1016/j.cclet.2010.07.023
  • Li, Y., Tian, K., Qin, A., Zhang, L., Huo, L., Lei, L. et al. (2014) Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARγ. European Journal of Medicinal Chemistry, 76, 182–192. https://doi.org/10.1016/j.ejmech.2014.02.024
  • Mao, W., Ning, M., Liu, Z., Zhu, Q., Leng, Y. and Zhang, A. (2012). Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. Bioorg. Medicinal Chemistry, 20(9), 2982–2991. https://doi.org/10.1016/j.bmc.2012.03.008
  • Matschinsky, F. M. and Porte, D. (2010) Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Medicine Reports, 2, 43. https://doi.org/10.3410/M2-43
  • Matschinsky, F. M., Zelent, B., Doliba, N., Li, C., Vanderkooi, J. M., Naji, A. et al. (2011). Glucokinase activators for diabetes therapy. Diabetes Care, 34, S236–S243. https://doi.org/10.2337/dc11-s236
  • Miteva, M. A., Guyon, F. and Tufféry, P. (2010). Frog2: Efficient 3D conformation ensemble generator for small compounds. Nucleic Acids Research, 38, W622–627. https://doi.org/10.1093/nar/gkq325
  • Mitsuya, M., Kamata, K., Bamba, M., Watanabe, H., Sasaki, Y., Sasaki, K. et al. (2009). Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorganic and Medicinal Chemistry Letters, 19(10), 2718–2721. https://doi.org/10.1016/j.bmcl.2009.03.137
  • Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. et al. (2009). Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. Journal of Computational Chemistry, 16, 2785–2791. https://doi.org/10.1002/jcc.21256
  • Olokoba, A. B., Obateru, O. A. and Olokoba, L. B. (2012). Type 2 diabetes mellitus: a review of current trends. Oman Medical Journal, 27, 269–273. https://doi.org/10.5001/omj.2012.68
  • Pal, M. (2009). Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discovery Today, 14, 784–792. https://doi.org/10.1016/j.drudis.2009.05.013
  • Pal, M. (2009a). Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Current Medicinal Chemistry, 16(29), 3858–3874. https://doi.org/10.2174/092986709789177993
  • Park, K., Lee, B. M., Kim, Y. H., Han, T., Yi, W., Lee, D.H. et al. (2013). Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus. Bioorganic and Medicinal Chemistry Letters, 23(2), 537–542. https://doi.org/10.1016/j.bmcl.2012.11.018
  • Park, K., Lee, M., Hyun, H., Lee, H., Choi, H., Kim, H. et al. (2014). Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1Hpyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bioorganic and Medicinal Chemistry, 22(7), 2280–2293. https://doi.org/10.1016/j.bmc.2014.02.009
  • Perseghin, G. (2010). Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 95(11), 4871–4873. https://doi.org/10.1210/jc.2010-2049
  • Pfefferkorn, J. A., Guzman-Perez, A., Litchfield, J., Aiello, R., Treadway, J. L., Pettersen, J., et al. (2012). Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol- 1-yl)propanamido) nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. Journal of Medicinal Chemistry, 55(3), 1318–1333. https://doi.org/10.1021/jm2014887
  • Pfefferkorn, J. A., Tu, M., Filipski, K. J., Guzman- Perez, A., Bian, J., Aspnes, G. E. et al. (2012a). The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Bioorganic and Medicinal Chemistry Letters, 22(23), 7100–7105. https://doi.org/10.1016/j.bmcl.2012.09.082
  • Pike, K. G., Allen, J. V., Caulkett, P. W., Clarke, D. S., Donald, C. S., Fenwick, M. L. et al. (2011). Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. Bioorganic and Medicinal Chemistry Letters, 21(11), 3467–3470. https://doi.org/10.1016/j.bmcl.2011.03.093
  • Sidduri, A., Grimsby, J. S., Corbett, W. L., Sarabu, R., Grippo, J. F., Lou, J. et al. (2010). 2,3-Disubstituted acrylamides as potent glucokinase activators. Bioorganic and Medicinal Chemistry Letters, 20(19), 5673-5676. https://doi.org/10.1016/j.bmcl.2010.08.029
  • Singh, R., Lather, V., Pandita, D., Vikramjeet, J., Karthikeyan, A. N. and Singh, A. S. (2016). Synthesis, docking and antidiabetic activity of some newer benzamide derivatives as potential glucokinase activators. Letters in Drug Design and Discovery, 14(5), 540–553. https://doi.org/10.2174/1570180813666160819125342
  • Takahashi, K., Hashimoto, N., Nakama, C., Kamata, K., Sasaki, K., Yoshimoto, R. et al. (2009). The design and optimization of a series of 2-(pyridin-2-yl)-1Hbenzimidazole compounds as allosteric glucokinase activators. Bioorganic and Medicinal Chemistry, 17(19), 7042–7051. https://doi.org/10.1016/j.bmc.2009.05.037
  • Trott, O., and Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. Journal of Computational Chemistry, 31, 455–461.
  • Tsumura, Y., Tsushima, Y., Tamura, A., Hasebe, M., Kanou, M., Kato, H. et al. (2017). TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models. PLoS One, 12(2), e0172252. https://doi.org/10.1371/journal.pone.0172252
  • Wang, Z., Shi, X., Zhang, H., Yu, L., Cheng, Y., Zhang, H. et al. (2017). Discovery of cycloalkylfused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 139, 128–152. https://doi.org/10.1016/j.ejmech.2017.07.051
  • Ye, N., Xu, X., Li, F., Ning, M., Liu, Z., Cao, Y. et al. (2012). Investigation on the oxidation of aryl oxiranylmethanols and the synthesis of 2-aryl-Nthiazolyl-oxirane-2-carboxamides as glucokinase activators. Tetrahedron Letters, 53(35), 4738–4742. https://doi.org/10.1016/j.tetlet.2012.06.111
  • Zhang, L., Chen, X., Liu, J., Zhu, Q., Leng, Y., Luo, X. et al. (2012). Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase. European Journal of Medicinal Chemistry, 58, 624–639. https://doi.org/10.1016/j.ejmech.2012.06.020
  • Zhang, L., Tian, K., Li, Y., Lei, L., Qin, A., Zhang, L. et al. (2012a). Novel phenyl-urea derivatives as dualtarget ligands that can activate both GK and PPARγ. Acta Pharmaceutica Sinica B, 2(6), 588–597. https://doi.org/10.1016/j.apsb.2012.10.002

How to Cite

Ajmer Singh Grewal, Kapil Sharma, Sukhbir Singh, Vikramjeet Singh, Deepti Pandita, Viney Lather. Design, Synthesis and Antidiabetic Activity of Novel Sulfamoyl Benzamide Derivatives as Glucokinase Activators. J. Pharm. Technol. Res. Manag.. 2018, 06, 115-124
Design, Synthesis and Antidiabetic Activity of Novel Sulfamoyl Benzamide Derivatives as Glucokinase Activators

Current Issue

PeriodicityBiannually
Issue-1May
Issue-2November
ISSN Print2321-2217
ISSN Online2321-2225
RNI No.CHAENG/2013/50088
OA Policy

Publisher's policy of the journal at Sherpa UK for the submitted, accepted, and published articles. Click OAPolicy

Plan-S Compliance

To check compliance, one has to use the Journal Check Tool (JCT). This tool provided by cOAlition S (European funders) for the researchers (fundee) to check the compliance with the journal.

Recommend journal to your library

You can recommend the journal being a researcher or faculty member to your library. We will post a copy of the Journal to your library on your behalf at free of cost.
Click here: Recommend Journal

Preprint Arxiv Submission

The authors are encouraged to submit the author’s copy (preprint) to appropriate preprint archives e.g. https://arxiv.org and/or on https://indiarxiv.org or institutional repositories (e.g., D Space) before paper acceptance by the editor of Journal. After publications of the paper author(s) should mention the citation information, title and abstract along with DOI number of the publication carefully on the required page of the depository(ies).

Contact: Phone: +91-172-2741000, +91-172-4691800

Email : editor.jptrm@chitkara.edu.in;

Abstract and Indexing

Information

This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles in Journal of Pharmaceutical Technology, Research and Management (J. Pharm. Tech. Res. Management) by Chitkara University Publications are Open Access articles that are published with licensed under a Creative Commons Attribution- CC-BY 4.0 International License. Based on a work at https://jptrm.chitkara.edu.in/. This license permits one to use, remix, tweak and reproduction in any medium, even commercially provided one give credit for the original creation.

View Legal Code of the above-mentioned license, https://creativecommons.org/licenses/by/4.0/legalcode

View Licence Deed here https://creativecommons.org/licenses/by/4.0/

Creative Commons License

Journal of Pharmaceutical Technology, Research and Management by Chitkara University Publications is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://jptrm.chitkara.edu.in//

Members

Chitkara University

Chitkara University

India’s top rated university

Chandigarh-Patiala National Highway, Punjab 140 401

Chandigarh Information Center SCO 160-161, Sector 9-C, Chandigarh 160 009

Publisher

Chitkara University Publications,
Administrative Office, Saraswati Kendra, P.O. Box No. 70, SCO 160-161, Sector- 9C, Chandigarh-160009, India.
Phone: +91-172-2741000, +91-172-4691800;
Email: chitkarauniversitypublications@chitkara.edu.in;
For all journals, please visit the website: https://publications.chitkara.edu.in/

The Journal of Pharmaceutical Technology, Research and Management is a peer-reviewed, refereed, bi-annual open-access journal of "Chitkara University Publications".  ISSN (p):2321-2217, ISSN (e): 2321-2225, RNI No.: CHAENG/2013/50088, Journal's DOI: https://doi.org/10.15415/jptrm

Copyright ©2023 Chitkara Educational Trust | All rights reserved
Explore Your Potential

Chandigarh-Patiala National Highway, Punjab 140 401

Chandigarh Information Center SCO 160-161, Sector 9-C, Chandigarh 160 009